OPKO Health, Inc. (0KCS.L)
USD 1.63
(0.62%)
USD 1.63
(0.62%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 65.69 Million USD | -11.29% |
| 2022 | 74.06 Million USD | -14.38% |
| 2021 | 86.5 Million USD | -34.64% |
| 2020 | 132.34 Million USD | 147.67% |
| 2019 | 53.43 Million USD | 26.32% |
| 2018 | 42.29 Million USD | -14.26% |
| 2017 | 49.33 Million USD | 4.46% |
| 2016 | 47.22 Million USD | 19.02% |
| 2015 | 39.68 Million USD | 138.98% |
| 2014 | 16.6 Million USD | -8.16% |
| 2013 | 18.07 Million USD | -18.79% |
| 2012 | 22.26 Million USD | 66.89% |
| 2011 | 13.33 Million USD | -18.78% |
| 2010 | 16.42 Million USD | 56.11% |
| 2009 | 10.52 Million USD | 158.92% |
| 2008 | 4.06 Million USD | 83.51% |
| 2007 | 2.21 Million USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 101 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 60.15 Million USD | 1.33% |
| 2024 Q1 | 59.36 Million USD | -9.64% |
| 2023 Q3 | 68.96 Million USD | -6.49% |
| 2023 Q1 | 75.41 Million USD | 1.82% |
| 2023 Q4 | 65.69 Million USD | -4.73% |
| 2023 Q2 | 73.74 Million USD | -2.2% |
| 2023 FY | 65.69 Million USD | -11.29% |
| 2022 Q1 | 99.4 Million USD | 14.92% |
| 2022 Q4 | 74.06 Million USD | 3.68% |
| 2022 FY | 74.06 Million USD | -14.38% |
| 2022 Q3 | 71.42 Million USD | -14.26% |
| 2022 Q2 | 83.3 Million USD | -16.2% |
| 2021 Q1 | 159.1 Million USD | 20.22% |
| 2021 FY | 86.5 Million USD | -34.64% |
| 2021 Q2 | 134.72 Million USD | -15.32% |
| 2021 Q4 | 86.5 Million USD | -23.36% |
| 2021 Q3 | 112.86 Million USD | -16.23% |
| 2020 Q2 | 72.96 Million USD | 24.31% |
| 2020 Q3 | 111.87 Million USD | 53.32% |
| 2020 Q4 | 132.34 Million USD | 18.3% |
| 2020 FY | 132.34 Million USD | 147.67% |
| 2020 Q1 | 58.69 Million USD | 9.85% |
| 2019 Q4 | 53.43 Million USD | 6.64% |
| 2019 Q3 | 50.1 Million USD | 3.76% |
| 2019 Q2 | 48.29 Million USD | 8.26% |
| 2019 FY | 53.43 Million USD | 26.32% |
| 2019 Q1 | 44.61 Million USD | 5.46% |
| 2018 Q3 | 43.37 Million USD | -7.22% |
| 2018 FY | 42.29 Million USD | -14.26% |
| 2018 Q4 | 42.29 Million USD | -2.49% |
| 2018 Q2 | 46.75 Million USD | -6.15% |
| 2018 Q1 | 49.81 Million USD | 0.98% |
| 2017 Q2 | 48.29 Million USD | 1.69% |
| 2017 Q1 | 47.49 Million USD | 0.56% |
| 2017 Q3 | 46.95 Million USD | -2.77% |
| 2017 FY | 49.33 Million USD | 4.46% |
| 2017 Q4 | 49.33 Million USD | 5.07% |
| 2016 Q2 | 42.04 Million USD | 3.63% |
| 2016 FY | 47.22 Million USD | 19.02% |
| 2016 Q3 | 43.18 Million USD | 2.71% |
| 2016 Q4 | 47.22 Million USD | 9.36% |
| 2016 Q1 | 40.57 Million USD | 2.25% |
| 2015 Q2 | 20.51 Million USD | 11.98% |
| 2015 Q1 | 18.32 Million USD | 10.36% |
| 2015 Q3 | 40.69 Million USD | 98.32% |
| 2015 Q4 | 39.68 Million USD | -2.49% |
| 2015 FY | 39.68 Million USD | 138.98% |
| 2014 FY | 16.6 Million USD | -8.16% |
| 2014 Q1 | 18.86 Million USD | 4.35% |
| 2014 Q2 | 18.33 Million USD | -2.81% |
| 2014 Q4 | 16.6 Million USD | -0.35% |
| 2014 Q3 | 16.66 Million USD | -9.12% |
| 2013 FY | 18.07 Million USD | -18.79% |
| 2013 Q2 | 19.77 Million USD | -14.09% |
| 2013 Q1 | 23.02 Million USD | 3.42% |
| 2013 Q3 | 19.51 Million USD | -1.32% |
| 2013 Q4 | 18.07 Million USD | -7.36% |
| 2012 Q3 | 21.48 Million USD | 25.76% |
| 2012 Q1 | 18.39 Million USD | 37.89% |
| 2012 FY | 22.26 Million USD | 66.89% |
| 2012 Q2 | 17.08 Million USD | -7.1% |
| 2012 Q4 | 22.26 Million USD | 3.6% |
| 2011 FY | 13.33 Million USD | -18.78% |
| 2011 Q4 | 13.33 Million USD | 26.84% |
| 2011 Q3 | 10.51 Million USD | -35.59% |
| 2011 Q2 | 16.32 Million USD | -9.99% |
| 2011 Q1 | 18.13 Million USD | -9.12% |
| 2010 Q3 | 13.86 Million USD | 17.34% |
| 2010 Q2 | 11.81 Million USD | 16.41% |
| 2010 Q1 | 10.15 Million USD | -3.49% |
| 2010 Q4 | 19.95 Million USD | 43.91% |
| 2010 FY | 16.42 Million USD | 56.11% |
| 2009 Q2 | 5.15 Million USD | 1.92% |
| 2009 Q3 | 5.44 Million USD | 5.75% |
| 2009 Q4 | 10.52 Million USD | 93.13% |
| 2009 FY | 10.52 Million USD | 158.92% |
| 2009 Q1 | 5.05 Million USD | 24.39% |
| 2008 Q1 | 2.5 Million USD | 13.23% |
| 2008 Q2 | 3.23 Million USD | 28.84% |
| 2008 Q4 | 4.06 Million USD | 82.12% |
| 2008 FY | 4.06 Million USD | 83.51% |
| 2008 Q3 | 2.23 Million USD | -30.93% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q4 | 2.21 Million USD | 0.0% |
| 2007 FY | 2.21 Million USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q1 | 101 Thousand USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q2 | 101 Thousand USD | 0.0% |
| 2006 Q3 | 101 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | 101 Thousand USD | 0.0% |
| 2005 Q4 | 101 Thousand USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Editas Medicine, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | -23.282% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 15.129% |
| Perrigo Company plc | 1.14 Billion USD | 94.242% |
| Illumina, Inc. | 587 Million USD | 88.808% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.709% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -533.407% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.21% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -56.013% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 97.454% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 516.23 Million USD | 87.274% |
| Biogen Inc. | 2.52 Billion USD | 97.401% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -497.354% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -2228.855% |
| bluebird bio, Inc. | 22.91 Million USD | -186.649% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -0.113% |
| FibroGen, Inc. | 41.56 Million USD | -58.058% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 93.628% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 26.304% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -10.053% |
| Myriad Genetics, Inc. | 20.1 Million USD | -226.851% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 97.438% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 2788.093% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 82.974% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 94.066% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 91.108% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -131.124% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -576.87% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 16.1 Million USD | -308.031% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -334.073% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 79.651% |
| Exelixis, Inc. | 17.32 Million USD | -279.247% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -71.533% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -749.897% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 12.02 Million USD | -446.382% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 21.22 Million USD | -209.556% |
| Insmed Incorporated | 83.24 Million USD | 21.083% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 48.514% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -244.396% |
| TG Therapeutics, Inc. | 39.82 Million USD | -64.973% |
| Incyte Corporation | 62.97 Million USD | -4.327% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 80.025% |